Reference designator · U08 · About
About TB-500 Compound, the board behind the reading
An independent editorial project that routes the published TB-500 record back to its sources — and is explicit about what it is not.
What this site is
TB-500 Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 — the Ac-LKKTETQ fragment of thymosin β4 — and its parent protein. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science, organized so a reader can trace each claim back to the study it came from.
The site treats the literature like a populated board: each finding is a component, each citation an identifier, and the central identity caveat — fragment versus full-length protein — is drawn as a labeled net rather than blurred. The dealt focus is the safety record, which is why the tumor-angiogenesis signal and the absence of a human safety profile for the fragment are surfaced first, not last.
Why "Compound" is a register, not a counter
The word "compound" in the domain name is editorial framing — the engineered, inspected register of a research board, a thing assembled and traced, not a pharmacy checkout. It is a position this publisher occupies relative to the literature, not a claim that the site compounds, dispenses, prescribes, or supplies anything. We do not sell TB-500, we do not source it, and we do not direct readers to anyone who does. The negative space on this board is deliberate: there is no price, no vendor, and no order path here, because that is not what an editorial digest is for.
Where the site discusses compounded access, it does so only in general regulatory terms drawn from authoritative FDA sources, and only to explain the framework — never to facilitate obtaining a substance. The TB-500 legal status and 503A category page is a compliance reading, not a storefront.
How we handle evidence
Every quantitative claim on this site is tied to a numbered citation in the TB-500 references and citations register, and each finding is tagged to the molecule it was measured on. We distinguish, throughout, the 889 Da Ac-LKKTETQ fragment from the 4963 Da full-length thymosin β4 protein, because most efficacy data belong to the parent and conflating them is the most common error in TB-500 writing. We report counter-evidence — the null mdx result, the non-monotonic dose response — on the same page as the positive findings, not in a separate, quieter place. When the human data run out, we say so.